You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,833,546


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,833,546
Title:Pharmaceutical dosage form and method for the production thereof
Abstract: The invention relates to a method for producing a pharmaceutical dosage form as tablets, pellets and/or in the form of an active ingredient-containing matrix, whereby the tablets, pellets and/or active ingredient-containing matrix contain a pharmaceutical active ingredient and a copolymer serving as a coating agent and/or binding agent, and optionally contain a core and pharmaceutically common additives. According to the invention, the copolymer, the pharmaceutical active ingredient, the optionally present core and/or the pharmaceutically common additives are processed using known techniques by melting, injection molding, extrusion, wet granulation, casting, dipping, spreading out, spraying on, or pressing to form tablets, pellets and/or an active ingredient-containing matrix. The inventive method is characterized in that a copolymer is used that consists of 20 to 34 wt. % methacrylic acid, 20 to 69 wt. % methylacrylate and 0 to 40 wt. % ethylacrylate and, optionally, of 0 to 10 wt. % of additional vinylically copolymerizable monomers with the provision that the glass transition temperature of the copolymer is no higher than 60.degree. C. according to ISO 11357-2, Item 3.3.3. The invention also relates to the pharmaceutical dosage form produced according to this method, said copolymer and the use thereof.
Inventor(s): Petereit; Hans-Ulrich (Darmstadt, DE), Suefke; Thomas (Erzhausen, DE), Meier; Christian (Darmstadt, DE), Schnabel; Michael (Biebesheim, DE), Blesing; Ingrid (Fuerth/Odenwald, DE), Grimm; Stefan (Wintersheim, DE)
Assignee: Evonik Roehm GmbH (Darmstadt, DE)
Application Number:10/502,648
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,833,546
Patent Claims:1. A drug form comprising an active ingredient and a copolymer comprising TABLE-US-00017 20 to 34% by weight methacrylic acid and/or acrylic acid, 20 to 69% by weight methyl acrylate and 0 to 40% by weight ethyl acrylate and/or,

optionally, 0 to 10% by weight further vinylically copolymerizable monomers, wherein the glass transition temperature of the copolymer is not more than 60.degree. C., and wherein the drug form does not release the active ingredient until a pH of about 5.8 to about 6.0.

2. The drug form as claimed in claim 1, wherein the drug form comprises tablets, tablets with delayed or accelerated disintegration, pellets, tablets compressed from pellets, pellets as a filling in capsules, a transdermal therapy system in the form of a patch or a swear, capsules, sachets, dried juices, suppositories, pessaries or implants.

3. The drug form as claimed in claim 1, wherein an active ingredient is present from the active ingredients class selected from the group consisting of the laxatives, analgesics, antibiotics, antirheumatics, antiallergics, antiarrhythmics, antibiotics, antiepileptics, beta-receptor blockers, calcium channel blockers, chemotherapeutics, enzymes, extracts, inhibitors of the rennin-angiotensin system, broncholytics/antasthmatics cholinergics, diuretics, circulation promoters, gout agents, influenza agents, coronary agents, osteoporosis agents lipid reducers, gastrointestinal agents, peptides, proteins, proton pump blockers, psychopharmaceuticals, platelet aggregation inhibitors, urological agents venous therapeutic agents, vitamins and minerals.

4. The drug form as claimed in claim 3, wherein the active ingredient is selected from the group consisting of paroxetine, reboxetine morphine tramadol, bisacodyl, sodium fluoride acamprosate Ca, digitoxin, dimethicone, coli bacteria, lipoic acid, methenamine, budenoside, acetylsalicylic acid, diclofenac, flurbiprophen, indometacin, lonazolac, hydrocortisone, ibuprofen, ketoprofen, prednisolone, propyphenazone, naproxen, paracetamol, flurbiprofen, dimetindene, quinidine, metoprolol, propranolol, oxprenolol, pindolol, atenolol, metoprolol, disopyramide, verapamil, diltiazem, gallopamil, nifedipine, nicardipine, nisoldipine, nimodipine, amlodipine, theophylline, salbutamol, terbutaline, ambroxol, aminophylline, carbamazepine, alendronate, etidronate, clodronate, pamidronate, ibandronate, choline theophyllinate, pyridostigmine, piretanide, furosemide, pentoxifylline, naftidrofuryl, buflomedil, xantinol nicotinate, bencyclane, allopurinol, norephedrine, clorphenamine isosorbide mononitrate, isosorbide dinitrate, glycerol trinitrate, molsidomine, bezafibrate, fenofibrate, gemfibrozil, cerivastatin, pravastatin, fluvastatin, lovastatin, atorvastatin, simvastatin, 5-aminosalicylic acid, sulfasalazine, budenoside, natamycin, preglumetacin sulfasalacine, nitrofurantion xantinol, metoclopramid, amitriptyline, dibenzepine, venlafaxin, thioridazine, oxazepam, omeprazole, lanzoprazole, pantoprazole, rabeprazole, perprazole, esomeprazole, nitrofurantoin, rutoside, garlic, aescin, bromelaine, pancreatin or trypsin, an insulin, a human growth hormone (hGH), corbaplatin, intron A, calcitonin, cromalyn, an interferon, a calcitonin, granulocyte colony stimulating factor (G-CSF), an interleukin, a kinine, parathyroid hormones, glucagon, pindolol, prosomatostatin, a somatostatin, detirelix, cetrorelix, vasopressin, 1-deaminocysteine-8-D-arginine vasopressin, leuprolide acetate, an antigen obtained from grasses, an antigen from rye, an antigen from wheat, an antigen from barley, an antigen from oats, an antigen from Bermuda grass, an antigen from horsetail, an antigen from maple, an antigen from elm, an antigen from oak, an antigen from plane, an antigen from poplar, an antigen from cedar, an antigen from horsetail, an antigen from thistles, an antigen from IgG, an antigen from a vaccine monoclonal antibodies, ascorbic acid, aspartamic acid, valproic acid zinc, potassium, sodium, lithium, their salts, and mixtures thereof.

5. A copolymer suitable for producing a drug form as claimed in claim 1.

6. The copolymer as claimed in claim 5, wherein the copolymer is in the form of a partly neutralized powder.

7. The copolymer as claimed in claim 5, wherein the copolymer is in powder form in a mixture with a pharmaceutically acceptable excipient in a readily redispersible form.

8. A method of producing a drug form, which comprises: incorporating the copolymer claimed in claim 5 into the drug form.

Details for Patent 7,833,546

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 10/28/1982 ⤷  Try a Trial 2022-02-27
Eli Lilly And Company HUMULIN R U-500 insulin human Injection 018780 12/29/2015 ⤷  Try a Trial 2022-02-27
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 08/06/1998 ⤷  Try a Trial 2022-02-27
Eli Lilly And Company HUMULIN R U-500 insulin human Injection 018780 03/31/1994 ⤷  Try a Trial 2022-02-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.